Literature DB >> 15546173

Is routine early invasive management of non-ST-segment elevation myocardial infarction beneficial in elderly patients?

Sheldon M Singh1, David A Alter.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15546173      PMCID： PMC526326          DOI： 10.1503/cmaj.1041543

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.

Authors:  H V Anderson; C P Cannon; P H Stone; D O Williams; C H McCabe; G L Knatterud; B Thompson; J T Willerson; E Braunwald
Journal:  J Am Coll Cardiol       Date:  1995-12       Impact factor: 24.094

Review 2.  Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature.

Authors:  Anthony A Bavry; Dharam J Kumbhani; Rene Quiroz; Suneil R Ramchandani; Satish Kenchaiah; Elliott M Antman
Journal:  Am J Cardiol       Date:  2004-04-01       Impact factor: 2.778

3.  Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators.

Authors:  W E Boden; R A O'Rourke; M H Crawford; A S Blaustein; P C Deedwania; R G Zoble; L F Wexler; R E Kleiger; C J Pepine; D R Ferry; B K Chow; P W Lavori
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

4.  Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial.

Authors:  Magnus Janzon; Lars-Ake Levin; Eva Swahn
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.